Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High-Risk Myeloid Leukemia.

Trial Profile

Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High-Risk Myeloid Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Feb 2012 Actual patient number (45) added as reported by ClinicalTrials.gov.
    • 17 Feb 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top